Evidence map›Paper›PMID 35961968›Full record

ArticleNature communications2022

Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.

Yexuan Deng, Sarah T Diepstraten, Margaret A Potts, Göknur Giner, Stephanie Trezise, Ashley P Ng, Gerry Healey, Serena R Kane, Amali Cooray, Kira Behrens and 13 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  10. Review
  11. Article
  12. Applications and advancements of CRISPR-Cas in the treatment of lung cancer.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Yexuan Deng *The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
Sarah T Diepstraten *The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Margaret A PottsThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9796-9683
Göknur GinerThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Stephanie TreziseThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7511-3291
Ashley P NgThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9690-0879
Gerry HealeyThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Serena R KaneThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Amali CoorayThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2981-9282
Kira BehrensThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-0800-8472
Amy HeidersbachDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Andrew J KuehThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Martin PalThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-1563-5426
Stephen WilcoxThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Lin TaiThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Warren S AlexanderThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Jane E VisvaderThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9173-6977
Stephen L NuttThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-0020-6637
Andreas StrasserThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-5020-4891
Benjamin HaleyDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Quan ZhaoThe State Key Laboratory of Pharmaceutical Biotechnology, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0002-8533-1938
Gemma L KellyThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-6533-1201
Marco J HeroldThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. herold@wehi.edu.au.ORCID http://orcid.org/0000-0001-7539-7581
The University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AUCharles Sturt University · AUNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR technologies have advanced cancer modelling in mice, but CRISPR activation (CRISPRa) methods have not been exploited in this context. We establish a CRISPRa mouse (dCas9a-SAM

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsLymphomaAnimalsBridged Bicyclo Compounds, HeterocyclicMiceProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycSulfonamidesBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycSulfonamidesvenetoclax

Identifiers

PMID35961968
PMCPMC9374748
OpenAlexW4290829989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.